References
- CRISP_ Special Edition August 2021.pdf. Available from: https://tinyurl.com/yc5c5v9e
- Ferrara N, Hillan KJ, Gerber HP, et al. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov. 2004;3(5):391–400. doi: 10.1038/nrd1381.
- Drug Approval Package: Avastin (Bevacizum) NDA #125085. [Internet]. [cited 2024 Mar 25]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/STN-125085_Avastin.cfm
- Avastin EPAR Scientific Discussion - 08/08/2007. [Internet]. [cited 2022 May 3]. Available from: https://www.ema.europa.eu/en/documents/scientific-discussion-variation/avastin-h-c-582-ii-0008-epar-scientific-discussion-variation_en.pdf
- Avastin EPAR Scientific Discussion - 12/10/2007. [Internet]. [cited 2022 May 3]. Available from: https://www.ema.europa.eu/en/documents/scientific-discussion-variation/avastin-h-c-582-ii-0009-epar-scientific-discussion-variation_en.pdf
- Phase IV of Drug Development - PMC [Internet]. [cited 2023 Jul 18]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3148611/
- Sahoo BM, Ravi Kumar BVV, Sruti J, et al. Drug repurposing strategy (DRS): emerging approach to identify potential therapeutics for treatment of novel coronavirus infection. Front Mol Biosci. 2021;8:628144. doi: 10.3389/fmolb.2021.628144.
- Fatemi N, Karimpour M, Bahrami H, et al. Current trends and future prospects of drug repositioning in gastrointestinal oncology. Front Pharmacol. 2023;14:1329244. [cited 2024 Mar 25]. Available from: https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2023.1329244
- El Bairi K, Trapani D, Petrillo A, et al. Repurposing anticancer drugs for the management of COVID-19. Eur J Cancer. 2020;141:40–61.
- Jose V, Radhakrishna S, Pipalava P, et al. Bevacizumab for eye diseases – legal, regulatory, and ethical overview. Indian J Pharmacol. 2019;51(6):377–383. doi: 10.4103/ijp.IJP_413_19.
- Bachu RD, Abou-Dahech M, Balaji S, et al. Oncology biosimilars: new developments and future directions. Cancer Rep (Hoboken). 2022;5(11):e1720. Epub 2022 Oct 4. PMID: 36195576; PMCID: PMC9675387. doi: 10.1002/cnr2.1720.
- Home | Beta ClinicalTrials.gov [Internet]. [cited 2023 Jul 18]. Available from: https://clinicaltrials.gov/
- Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971;285(21):1182–1186. doi: 10.1056/NEJM197111182852108.
- Avastin: EPAR - Scientific Discussion. First published 24/01/2006 [Internet]. [cited 2024 Mar 25]. Available from: https://www.ema.europa.eu/en/documents/scientific-discussion/avastin-epar-scientific-discussion_en.pdf
- Yorston D. Anti-VEGF drugs in the prevention of blindness. Community Eye Health. 2014;27(87):44–46. PMID: 25918459; PMCID: PMC4322736.
- Würdinger T, Tannous BA. Glioma angiogenesis: towards novel RNA therapeutics. Cell Adh Migr. 2009;3(2):230–235. Epub 2009 Apr 22. PMID: 19262177; PMCID: PMC2679892. doi: 10.4161/cam.3.2.7910.
- Pushpakom S, Iorio F, Eyers P, et al. Drug repurposing: progress, challenges and recommendations. Nat Rev Drug Discov. 2019;18(1):41–58. doi: 10.1038/nrd.2018.168.
- Hernandez JJ, Pryszlak M, Smith L, et al. Giving drugs a second chance: overcoming regulatory and financial hurdles in repurposing approved drugs as cancer therapeutics. Front Oncol. 2017;7:273. [cited 2023 Jan 8]. Available from: doi: 10.3389/fonc.2017.00273.
- Research and Markets. Drug repurposing service providers market, 2020–2030. Roots Analysis Private Ltd; 2020 Jul; ID: 5141824 [Internet]. [cited 2023 Jan 10]. Available from: https://www.researchandmarkets.com/reports/5141824/drug-repurposing-service-providers-market-2020
- Cha Y, Erez T, Reynolds IJ, et al. Drug repurposing from the perspective of pharmaceutical companies. Br J Pharmacol. 2018;175(2):168–180. Jan
- Lee HS, Bae T, Lee J-H, et al. Rational drug repositioning guided by an integrated pharmacological network of protein, disease and drug. BMC Syst Biol. 2012;6(1):80. doi: 10.1186/1752-0509-6-80.
- Commissioner O of the FDA. Real-world evidence; FDA; 2023. [cited 2023 Jul 19]. Available from: https://www.fda.gov/science-research/science-and-research-special-topics/real-world-evidence
- Schad F, Thronicke A. Real-world evidence—current developments and perspectives. Int J Environ Res Public Health. 2022;19(16):10159. doi: 10.3390/ijerph191610159.
- Martin L, Hutchens M, Hawkins C, et al. How much do clinical trials cost? Nat Rev Drug Discov. 2017;16(6):381–382. doi: 10.1038/nrd.2017.70.
- Karanicolas PJ, Farrokhyar F, Bhandari M. Blinding: who, what, when, why, how? Can J Surg. 2010;53(5):345–348.
- Bigirumurame T, Uwimpuhwe G, Wason J. Sequential multiple assignment randomized trial studies should report all key components: a systematic review. J Clin Epidemiol. 2022;142:152–160. doi: 10.1016/j.jclinepi.2021.11.007.
- Kidwell KM, Postow MA, Panageas KS. Sequential, multiple assignment, randomized trial designs in immuno-oncology research. Clin Cancer Res. 2018;24(4):730–736. doi: 10.1158/1078-0432.CCR-17-1355.
- D'Amato RJ, Loughnan MS, Flynn E, et al. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA. 1994;91(9):4082–4085. doi: 10.1073/pnas.91.9.4082.
- Repurposing Drugs. | National Center for Advancing Translational Sciences. [Internet]. [cited 2023 Jan 15]. Available from: https://ncats.nih.gov/preclinical/repurpose
- Hurwitz HI, Yi J, Ince W, et al. The clinical benefit of bevacizumab in metastatic colorectal cancer is independent of K-ras mutation status: analysis of a phase III study of bevacizumab with chemotherapy in previously untreated metastatic colorectal cancer. Oncologist. 2009;14(1):22–28. doi: 10.1634/theoncologist.2008-0213.
- EMA (European Medicines Agency). Medicines. [cited 2023 Feb 6]. Available from: https://www.ema.europa.eu/en/medicines/field_ema_web_categories%253Aname_field/Human/ema_group_types/ema_medicine/field_ema_med_status/authorised-36/ema_medicine_types/field_ema_med_biosimilar/search_api_aggregation_ema_medicine_types/field_ema_med_biosimilar
- Koyfman H. Biosimilarity and interchangeability in the biologics price competition and innovation act of 2009 and FDA’s 2012 draft guidance for industry. Biotechnol Law Rep. 2013;32(4):238–251. doi: 10.1089/blr.2013.9884.
- Schiestl M, Zabransky M, Sörgel F. Ten years of biosimilars in Europe: development and evolution of the regulatory pathways. Drug Des Devel Ther. 2017;11:1509–1515.
- avastin-epar-product-information_en.pdf. [Internet]. [cited 2023 Jul 19]. Available from: https://www.ema.europa.eu/en/documents/product-information/avastin-epar-product-information_en.pdf